Genital Neoplasms, Male clinical trials at UCSD

• P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  open to eligible males ages 18 years and up

  An open-label, multi-center, single and cyclic ascending dose study of P-PSMA-101 autologous CAR-T cells in patients with mCRPC.

  San Diego, California and other locations

Last updated: April 28, 2021